BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 37926876)

  • 1. Frequency of TP53 Mutation in B-Cell Chronic Lymphocytic Leukaemia and its Association with Lymphocyte Doubling Time.
    Ali SM; Irfan SM; Raza N
    J Coll Physicians Surg Pak; 2023 Nov; 33(11):1249-1253. PubMed ID: 37926876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequency Of TP53 Gene Mutation In Patients With Chronic Lymphocytic Leukaemia.
    Qadir H; Nasir N; Qadir N; Adil SN; Tanzeem H; Qadir A
    J Ayub Med Coll Abbottabad; 2020; 32(4):523-526. PubMed ID: 33225656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relevance of TP53 for CLL diagnostics.
    Catherwood MA; Gonzalez D; Donaldson D; Clifford R; Mills K; Thornton P
    J Clin Pathol; 2019 May; 72(5):343-346. PubMed ID: 30712002
    [No Abstract]   [Full Text] [Related]  

  • 4. Characterisation of TP53 abnormalities in chronic lymphocytic leukaemia.
    Thornton PD; Gruszka-Westwood AM; Hamoudi RA; Atkinson S; Kaczmarek P; Morilla RM; Hilditch BL; A'Hern R; Matutes E; Catovsky D
    Hematol J; 2004; 5(1):47-54. PubMed ID: 14745430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of ATM and TP53 deletions in Chinese patients with chronic lymphocytic leukemia.
    Xu W; Li JY; Wu YJ; Yu H; Shen QD; Li L; Fan L; Qiu HX
    Leuk Res; 2008 Jul; 32(7):1071-7. PubMed ID: 18035414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial.
    Farooqui MZ; Valdez J; Martyr S; Aue G; Saba N; Niemann CU; Herman SE; Tian X; Marti G; Soto S; Hughes TE; Jones J; Lipsky A; Pittaluga S; Stetler-Stevenson M; Yuan C; Lee YS; Pedersen LB; Geisler CH; Calvo KR; Arthur DC; Maric I; Childs R; Young NS; Wiestner A
    Lancet Oncol; 2015 Feb; 16(2):169-76. PubMed ID: 25555420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial.
    Gonzalez D; Martinez P; Wade R; Hockley S; Oscier D; Matutes E; Dearden CE; Richards SM; Catovsky D; Morgan GJ
    J Clin Oncol; 2011 Jun; 29(16):2223-9. PubMed ID: 21483000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic and therapeutic stratification in CLL: focus on 17p deletion and p53 mutation.
    Buccheri V; Barreto WG; Fogliatto LM; Capra M; Marchiani M; Rocha V
    Ann Hematol; 2018 Dec; 97(12):2269-2278. PubMed ID: 30315344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lymphocyte doubling time in chronic lymphocytic leukemia modern era: a real-life study in 848 unselected patients.
    Baumann T; Moia R; Gaidano G; Delgado J; Condoluci A; Villamor N; Payedimarri AB; Costa D; Patriarca A; Jiménez-Vicente C; Rossi D; Montserrat E
    Leukemia; 2021 Aug; 35(8):2325-2331. PubMed ID: 33542480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TP53 Pro72 allele potentially increases the poor prognostic significance of TP53 mutation in chronic lymphocytic leukemia.
    Dong HJ; Fang C; Wang L; Fan L; Xu J; Wu JZ; Lu TX; Li JY; Xu W
    Med Oncol; 2014 Apr; 31(4):908. PubMed ID: 24615009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TP53 Mutations are infrequent in newly diagnosed chronic lymphocytic leukemia.
    Zainuddin N; Murray F; Kanduri M; Gunnarsson R; Smedby KE; Enblad G; Jurlander J; Juliusson G; Rosenquist R
    Leuk Res; 2011 Feb; 35(2):272-4. PubMed ID: 20870288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p53 expression in B-cell chronic lymphocytic leukemia: a marker of disease progression and poor prognosis.
    Cordone I; Masi S; Mauro FR; Soddu S; Morsilli O; Valentini T; Vegna ML; Guglielmi C; Mancini F; Giuliacci S; Sacchi A; Mandelli F; Foa R
    Blood; 1998 Jun; 91(11):4342-9. PubMed ID: 9596683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia.
    Pospisilova S; Gonzalez D; Malcikova J; Trbusek M; Rossi D; Kater AP; Cymbalista F; Eichhorst B; Hallek M; Döhner H; Hillmen P; van Oers M; Gribben J; Ghia P; Montserrat E; Stilgenbauer S; Zenz T;
    Leukemia; 2012 Jul; 26(7):1458-61. PubMed ID: 22297721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. THE SPECTRUM OF TP53, SF3B1, AND NOTCH1 MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS EXPOSED TO IONIZING RADIATION DUE TO THE CHORNOBYL NPP ACCIDENT.
    Bilous NI; Abramenko IV; Chumak AA; Dyagil IS; Martina ZV; Saenko V; Bazyka DA
    Probl Radiac Med Radiobiol; 2018 Dec; 23():283-301. PubMed ID: 30582853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial.
    Zenz T; Häbe S; Denzel T; Mohr J; Winkler D; Bühler A; Sarno A; Groner S; Mertens D; Busch R; Hallek M; Döhner H; Stilgenbauer S
    Blood; 2009 Sep; 114(13):2589-97. PubMed ID: 19643983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TP53 mutation and survival in chronic lymphocytic leukemia.
    Zenz T; Eichhorst B; Busch R; Denzel T; Häbe S; Winkler D; Bühler A; Edelmann J; Bergmann M; Hopfinger G; Hensel M; Hallek M; Döhner H; Stilgenbauer S
    J Clin Oncol; 2010 Oct; 28(29):4473-9. PubMed ID: 20697090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PRIMA-1
    Jaskova Z; Pavlova S; Malcikova J; Brychtova Y; Trbusek M
    Leuk Res; 2020 Feb; 89():106288. PubMed ID: 31924585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An ultra-deep sequencing strategy to detect sub-clonal TP53 mutations in presentation chronic lymphocytic leukaemia cases using multiple polymerases.
    Worrillow L; Baskaran P; Care MA; Varghese A; Munir T; Evans PA; O'Connor SJ; Rawstron A; Hazelwood L; Tooze RM; Hillmen P; Newton DJ
    Oncogene; 2016 Oct; 35(40):5328-5336. PubMed ID: 27041575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential prognosis of single and multiple TP53 abnormalities in high-count MBL and untreated CLL.
    Griffin R; Wiedmeier-Nutor JE; Parikh SA; McCabe CE; O'Brien DR; Boddicker NJ; Kleinstern G; Rabe KG; Bruins L; Brown S; Bonolo de Campos C; Ding W; Leis JF; Hampel PJ; Call TG; Van Dyke DL; Kay NE; Cerhan JR; Yan H; Slager SL; Braggio E
    Blood Adv; 2023 Jul; 7(13):3169-3179. PubMed ID: 36877634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comprehensive study of TP53 mutations in chronic lymphocytic leukemia: Analysis of 1287 diagnostic and 1148 follow-up CLL samples.
    Pekova S; Mazal O; Cmejla R; Hardekopf DW; Plachy R; Zejskova L; Haugvicova R; Jancuskova T; Karas M; Koza V; Smolej L; Bezdickova L; Kozak T
    Leuk Res; 2011 Jul; 35(7):889-98. PubMed ID: 21232794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.